Medication info
Phaesidapa M Extended Release Tablet 10/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Phaesidapa M Extended Release Tablet 10/500 mg (Dapagliflozin Propanediol Hydrate, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›500mg / 1 tabletDapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
Daiwoo Bio Co., Ltd.
Appearance
Pink rectangular extended release film-coated tablet
Packaging
30 tablets/box [(6 tablets/PTP) X 5], 30 tablets/bottle
Approval status
Active

MFDS item code 202302567 · Approved 2023.08.30 · Insurance code 694004090

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally taken once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Since any change may cause alterations in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. Discontinue this medicine immediately if the eGFR falls below 45 mL/min/1.73m2. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and elderly patients are more likely to have decreased renal function; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).

Ingredients

Manufacturer
Daiwoo Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication is used as an adjunct to dietary and exercise therapy to help control blood glucose levels in adult patients with type 2 diabetes who are appropriate candidates for combined treatment with dapagliflozin and metformin. It should be administered particularly when blood glucose is not adequately controlled and should be used with caution in patients with cardiovascular diseases or risk factors. This medication effectively improves blood glucose control and aids overall diabetes management.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally taken once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is 1 tablet of 5mg/500mg or 10mg/500mg once daily. Adjust the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients switching to this medicine from combination therapy with dapagliflozin and metformin, this medicine may be started at the previous doses of dapagliflozin and metformin. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dose adjusted appropriately. The safety and efficacy of this medicine have not been specifically evaluated in patients switching from other glucose-lowering medicines. Since any change may cause alterations in glycemic control, changes in the treatment of patients with type 2 diabetes should be made under careful monitoring. Swallow this medicine whole. Do not crush, cut, or chew it. Occasionally, inactive ingredients in this medicine may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dose adjustment is necessary for patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2 who have no other conditions that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. Discontinue this medicine immediately if the eGFR falls below 45 mL/min/1.73m2. Renal function should be assessed every 3~6 months. Elderly patients Metformin is excreted by the kidneys, and elderly patients are more likely to have decreased renal function; therefore, this medicine should be used with caution as age increases (see Precautions for Use, 9. Use in Elderly Patients).

Precautions

This medication helps to control blood glucose levels. However, it can rarely cause a serious condition called lactic acidosis, which requires caution. Be careful, as hypoglycemia can occur when taken with other diabetes medications. It should not be used in patients with significantly impaired kidney function or in conditions such as severe infection, dehydration, or acute myocardial infarction. Pregnant and breastfeeding women should also not take this medication. Elderly patients or those with weakened kidney function should ensure that kidney function is monitored prior to and during use of this medication. This medication can increase the risk of genital infections and urinary tract infections, so treatment should be sought promptly if symptoms appear. Dehydration or hypotension symptoms due to reduced fluid volume may also occur, requiring caution. Vitamin B12 deficiency may occur, so regular blood tests are recommended if taken for an extended period. Excessive alcohol consumption can increase risks, and it is advisable to avoid drinking alcohol. Before surgery or radiographic examinations with contrast agents, the medication should be discontinued for a period and resumed only after confirming normal kidney function. During treatment with this medication, be vigilant for hypoglycemic symptoms, and dosage adjustments may be necessary if taken with insulin or other hypoglycemic agents. In case of overdose, seek medical attention immediately for proper treatment. This medication is not used in children or pregnant women as its safety has not been established. This medication does not significantly affect the ability to drive or operate machinery, but dizziness may occur, so caution is advised. Store the medication out of reach of children and in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvovaginitis
  • balanitis
  • related genital infections
  • urinary tract infections
  • fungal infections
  • hypoglycemia
  • fluid volume depletion
  • thirst
Show 84 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar pruritus
  • genital pruritus
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated serum urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • malignant lung neoplasm
  • uterine fibroids
  • atrial fibrillation
  • acute cholecystitis
  • epigastric pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory abnormalities
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • herpes zoster
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood sugar
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periarticular inflammation
  • tendinitis
  • trigger finger
  • myasthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • pruritus
  • palpitations
  • insomnia
  • type 2a hyperlipidemia
  • sensorineural hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it must be stored in a well-sealed container. It is important to maintain the storage temperature between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pink rectangular extended release film-coated tablet

Package unit

30 tablets/box [(6 tablets/PTP) X 5], 30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.